The DOI matches its Crossref record.
The safety of gadolinium in patients with stage 3 and 4 renal failure
Abstract
BACKGROUND: Although there is a well-documented risk of acute renal failure (ARF) with the iodinated contrast agents, intravenous gadolinium-based contrast agents are considered non-nephrotoxic and have been widely used for magnetic resonance imaging (MRI). However, debate continues regarding the safety issue of gadolinium, especially in patients with kidney failure. Therefore, we aimed to evaluate the safety of gadolinium in patients with stage 3 and 4 renal failure as well as risk factors for nephrotoxicity. METHOD: We retrospectively analysed 473 patients with chronic renal failure who underwent angiographic MRI procedures in our centre from February 1999 to March 2005 in whom gadolinium was used as the sole contrast agent at a dose of 0.2 ml/kg. Among them, 91 patients with stage 3 or 4 renal failure according to K/DOQI definition, who had available data in their files, were enrolled in the study. The ARF was defined as an increase of at least 0.5 mg/dl in serum creatinine level over baseline after using gadolinium. RESULTS: Eleven of 91 (52 males, 39 females; median age 59 years; median estimated glomerular filtration rate (eGFR) 33 ml/min/1.73 m2) patients developed ARF (12.1%). The median eGFR was lower in patients with ARF than in those who did not develop ARF. The risk factors for ARF were baseline eGFR, older age, diabetic nephropathy and low baseline haemoglobin and albumin levels. Baseline eGFR and diabetic nephropathy were determined as the independent risk factors in regression analysis. CONCLUSIONS: An ARF can occur after gadolinium-based contrast agents in patients with moderate to severe chronic renal failure. Risk factors for ARF after gadolinium toxicity include diabetic nephropathy and low GFR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines
on behalf of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR), Stacul, F., van der Molen, A. J., Reimer, P., Webb, J. A. W., Thomsen, H. S., Morcos, S. K., Almén, T., Aspelin, P., Bellin, M.-F., et al. (2011) · European Radiology · doi:10.1007/s00330-011-2225-0 · Cited by 884
Davenport, M. S., Perazella, M. A., Yee, J., Dillman, J. R., Fine, D., McDonald, R. J., Rodby, R. A., Wang, C. L., & Weinreb, J. C. (2020) · Radiology · doi:10.1148/radiol.2019192094 · Cited by 601
Renal Vulnerability to Drug Toxicity
Perazella, M. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02050309 · Cited by 403
What nephrologists need to know about gadolinium
Penfield, J. G., & Reilly, R. F. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0660 · Cited by 335
Incorporation of excess gadolinium into human bone from medical contrast agents
Darrah, T. H., Prutsman-Pfeiffer, J. J., Poreda, R. J., Ellen Campbell, M., Hauschka, P. V., & Hannigan, R. E. (2009) · Metallomics · doi:10.1039/b905145g · Cited by 299
Metadata
- Authors
- Ergün, I., Keven, K., Uruç, I., Ekmekçi, Y., Canbakan, B., Erden, I., & Karatan, O.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-02
- Volume
- 21
- Issue
- 3
- Pages
- 697-700
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2107934382
- Cited by
- 158
- References
- 0
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety of gadolinium in patients with stage 3 and 4 renal failure. https://app.cochat.ai/papers/10.1093/ndt/gfi304
- The paper
- Ergün, I., Keven, K., Uruç, I., Ekmekçi, Y., Canbakan, B., Erden, I., & Karatan, O. (2006). The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfi304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.